Pérol M, et al. - In this post hoc analysis of the REVEL study [wherein ramucirumab plus docetaxel vs placebo plus docetaxel showed improved efficacy without further impairing quality of life, symptoms, or functioning in previously treated advanced/metastatic non-small-cell lung cancer (NSCLC)], researchers focused on the link between baseline Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) and efficacy. The average of the 6 LCSS symptom components was considered as baseline ASBI scores. In this large second-line cohort of patients with advanced NSCLC, baseline ASBI could be an independent prognostic factor. In the high symptom burden cohort, preservation of improved progression-free survival and overall survival was seen, which was indicative of the benefit of adding ramucirumab to docetaxel in the treatment of patients with greater symptom burden; this finding was consistent with earlier data on REVEL patients with aggressive disease.